Siga(SIGA)
NEW YORK, NYBiotechnology
Focus: Siga is a small-molecule biotech focused on infectious diseases, with a peak-stage product (TPOXX/tecovirimat) addressing orthopoxviral threats including smallpox and mpox. Public company generating $140M in FY2025 revenue with strong profitability ($68M net income).
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Siga
AI assessmentNot HiringNo open roles listed right now. Follow Siga to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Siga's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
1 in 5yr
TPOXX
Hiring
Stable
Revenue
$140M
Key Products
Peak5.8yr
Approved NDA for cytochrome P450 3A induction; primary revenue driver with Phase 3–4 pipeline expansion in oral and IV formulations.
Help build intelligence for Siga
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.